Anti-PD-1/PDL-1 therapy has been approved for the treatment of several cancer types, including metastatic melanoma, non-small cell lung cancer (NSCLC), head and neck cancers, urothelial carcinoma and others (118). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.